Microbot Medical Inc.

Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System

Microbot Medical signed ELMNT IR, a California-based outpatient interventional radiology practice, as the first Office-Based Laboratory customer in the world for the LIBERTY Endovascular Robotic System. ELMNT IR is also the company's first West Coast customer, ordering up to a 12-month supply of LIBERTY devices, with procedures already performed including Y90 mapping, prostate artery embolization, and genicular artery embolization. Management notes every customer that has used its initial LIBERTY inventory has reordered, and frames OBLs as a rapidly growing segment outside traditional hospital settings under its Full Market Release strategy.

•5d ago

Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.

Microbot Medical announced its executives and commercial team will attend the SIR EDGE 2026 conference in Louisville, Kentucky, alongside the ACIR Annual Fall Conference. The company frames the events as opportunities to engage hospital decision-makers, manage leads through Value Analysis Committee processes, and set up demonstrations as it expands its U.S. sales footprint. LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The release contains no financial figures or new commercial metrics.

•9d ago

Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio

Microbot Medical received several new patent approvals across the U.S., Japan, China and Canada, bringing its portfolio to 44 issued patents and 49 pending applications. The company says the strengthened IP estate supports commercial expansion of its LIBERTY Endovascular Robotic System in the U.S. and positions it for EU market entry as it pursues a CE Mark. LIBERTY remains the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures; the announcement contains no new financial or clinical data.

•12d ago

Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel

Microbot Medical signed a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System throughout Israel. The agreement follows Israeli Ministry of Health AMAR regulatory approval and registry listing in May 2026, with initial orders anticipated in Q4 2026. The deal advances Microbot's international strategy of engaging distributors in developed markets ahead of potential entry outside the U.S., though no financial terms were disclosed.

•26d ago

Microbot Medical® Highlights Growth Strategy

Microbot Medical outlined its commercial growth strategy at a New York analyst meeting, confirming it is on track for 12 U.S. sales territories by year-end. The company secured its first California customer and is expanding into the western U.S., while engaging Value Analysis Committees at multiple health systems to accelerate hospital adoption of the LIBERTY System. Management expects positive gross margins in 2027 following manufacturing efficiencies, and anticipates a CE mark decision in late Q4 2026 or early Q1 2027, with international expansion into Asia and the Middle East in advanced stages.

•1mo ago

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Microbot Medical filed its Q2 2026 Form 10-Q, reporting over 100% sequential growth in both revenue and customers driven by the Full Market Release of the LIBERTY System. Commercial expansion accelerated with new health system adoptions in four states, entry into federal healthcare via Lovell Government Services, and an expansion of sales territories from four to eight. Strategic milestones include Israel granting the first international marketing clearance for LIBERTY, a manufacturing partnership with Sanmina to scale production, and receipt of the 2026 Innovative Start-Up Award.

•2mo ago

Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026

Microbot Medical reported greater than 100% sequential revenue and customer growth in the second quarter of 2026, driven by the Full Market Release of the LIBERTY Endovascular Robotic System. Adoption expanded into health systems across Massachusetts, North Carolina, Michigan, and Pennsylvania, while procedure volumes increased at existing sites following the April launch. The company secured a government channel partnership with Lovell Government Services to target federal healthcare systems and received Israeli regulatory clearance, adding to plans to expand U.S. sales territories to 12 by year-end.

•3mo ago

Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader

Microbot Medical entered into a Letter of Agreement with Sanmina Corporation to manufacture the LIBERTY Endovascular Robotic System, aiming to increase capacity to meet rising domestic and international demand. The partnership is expected to diversify manufacturing capabilities, improve operating efficiencies, lower costs, and expand gross margins as the company scales production. Management cited growing adoption in the Eastern U.S., recent regulatory clearance in Israel, and progress toward CE Mark as key drivers for the expansion.

•4mo ago

Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System

Microbot Medical won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY Endovascular Robotic System, recognizing its technological and commercial progress. The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, with usage expanding to leading academic centers across seven states since its April full market release. CEO Harel Gadot highlighted that the award validates the company's mission to transform healthcare through innovation and establish a new category of surgical robotics.

•4mo ago

Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical announced the first health system adoption of its LIBERTY Endovascular Robotic System in Pennsylvania by a globally recognized academic center, expanding its footprint in the Northeast U.S. The company now has accounts across seven states in the Eastern U.S. and recently transitioned to full market release in the second quarter, with plans to expand sales territory to the West Coast. Additionally, a recent agreement to expand access to U.S. federal healthcare systems serving veterans and military populations is expected to support accelerating adoption.

•4mo ago

Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations

Microbot Medical partnered with Lovell Government Services to distribute the LIBERTY Endovascular Robotic System to federal healthcare systems including the VA, Military Health System, and Indian Health Service. The agreement places LIBERTY on Lovell’s Federal Supply Schedule contract with activation expected in Q3 2026, streamlining procurement for 170 federal medical centers. Lovell Government Services, a Service-Disabled Veteran-Owned Small Business, serves thousands of government care sites averaging over 200 peripheral endovascular cases annually per site.

•4mo ago

Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical announced that a major healthcare system in Michigan has adopted the LIBERTY Endovascular Robotic System, marking the first adoption in the state and the greater Midwest U.S. This follows a recent adoption in North Carolina, signaling expanding commercial presence across strategic U.S. regions and validating the company's transition to full market release. Separately, the company received regulatory approval from the Israeli Ministry of Health's AMAR Division, allowing it to market and sell the LIBERTY System in Israel.

•4mo ago

Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical secured its first North Carolina-based healthcare system customer for the LIBERTY Endovascular Robotic System. This adoption marks a geographic expansion into the Southeast, joining existing penetration in the Mid-Atlantic and Northeast U.S. CEO Harel Gadot cited the deal as evidence of accelerating account growth following the system's full market release.

•4mo ago

Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System

Microbot Medical received its first international regulatory approval for the LIBERTY Endovascular Robotic System from Israel's AMAR Division. This clearance allows the company to market and commercialize the system in Israel, serving as the second jurisdiction after the U.S. to approve the device. The approval also enables Microbot to obtain a Free Sale Certificate, which supports submissions for commercial activities in additional jurisdictions, including the EU where CE Mark certification is targeted for late 2026.

•5mo ago

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

Microbot Medical reported commercial adoption of its LIBERTY Endovascular Robotic System by multiple accounts, including two sites from the pivotal ACCESS-PVI clinical trial, marking early progress in its full market release. The company is leveraging updated medical guidelines regarding radiation and ergonomics and recently appointed Alon Tamir as VP of Sales, EMEA to support international commercialization efforts. Management plans to build on this momentum at the upcoming GEST conference in New York City, targeting over 1,000 global specialists to further expand its commercial infrastructure.

•5mo ago

Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®

Microbot Medical highlighted updated occupational protection guidelines from SIR and CIRSE, which address radiation exposure and ergonomic risks for interventional radiology staff. The company positions its LIBERTY robotic system as a solution to these specific challenges, noting that remote operation capabilities reduce physical strain and radiation exposure for physicians. At least nine medical societies, including the AMA, have endorsed initiatives to strengthen protections, reinforcing the commercial relevance of safety-focused technology.

•6mo ago